What this study is
First, the investigators plan to use a retrospective analysis to determine the clinical landscape of neurofibromatosis (NF)1-associated malignant peripheral nerve sheath tumor (MPNST) and precursor lesions (e.g., atypical or nodular plexiform neurofibromas). A worldwide database will be established, collecting, in a standardized manner, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from centers worldwide with expertise in these NF1-related cancers. Although retrospective in nature, the resulting data from this registry may reveal previously unanticipated patterns, similar to the INFACT effort outcome. This registry would then allow the acquisition of data associated with MPNST biospecimens collected under associated banks (frozen or paraffin-embedded, germline (or normal tissue DNA) samples, and any previously somatic whole-exome or whole-genome sequencing data for aggregate analyses). Second, the investigators plan to co-register patients to institutional banks in order to prospectively collect MPNST samples for analysis. These patients will be consented in order to collect the above information and for banking of tumor tissue and future studies that include genomic characterization of the tumors.
Study details
- Sponsor
- Washington University School of Medicine
- Conditions
- Malignant Peripheral Nerve Sheath Tumors
- Enrolling
- 1,050 people
- Starts
- 2017-04-28
- Est. completion
- 2053-04-30
- Record
- View on ClinicalTrials.gov ↗
Who can join
Sex ALLHealthy volunteers Not acceptedYou may qualify if
- Any patient diagnosed with an MPNST is eligible for enrollment to this registry provided s/he consents to participate (or consent form his/her parent or legal guardian or legally authorized representative is obtained).
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (13)
7 openJohns Hopkins
Baltimore, Maryland, United States
- Christine Pratilas, M.D. · Contact410-955-8751
- Christine Pratilas, M.D. · Principal investigator
RecruitingNational Institutes of Health (NIH)
Bethesda, Maryland, United States
- Jack F Shern, M.D. · Contact301-402-1444john.shern@nih.gov
- Jack F Shern, M.D. · Principal investigator
Not yet recruitingWashington University School of Medicine
St Louis, Missouri, United States
- Angela Hirbe, M.D., Ph.D. · Contact(314) 362-8965hirbea@wustl.edu
- Angela Hirbe, M.D., Ph.D. · Principal investigator
- David Gutmann, M.D., Ph.D. · Sub-investigator
- Sonika Dahiya, M.D., MBBS · Sub-investigator
- Brian Van Tine, M.D., Ph.D. · Sub-investigator
- Peter Oppelt, M.D. · Sub-investigator
RecruitingMemorial Sloan Kettering Cancer Center
New York, New York, United States
- Ping Chi, M.D., Ph.D. · Contact646-888-4166
- Ping Chi, M.D., Ph.D. · Principal investigator
Not yet recruitingMoffitt Cancer Center
Tampa, Florida, United States
CompletedDana Farber Cancer Institute
Boston, Massachusetts, United States
WithdrawnUniversity of Minnesota
Minneapolis, Minnesota, United States
WithdrawnLifespan
Providence, Rhode Island, United States
CompletedUniversity of Utah
Salt Lake City, Utah, United States
Completed
4 sites outside the US
Mount Sinai
Toronto, Ontario, Canada
- Jay Wunder, M.D. · Contact416-586-5995jay.wunder@sinaihealthsystem.ca
- Jay Wunder, M.D. · Principal investigator
RecruitingNagoya University Hospital
Nagoya, Showa Ward, Japan
- Yoshihiro Nishida, M.D., Ph.D. · Contact+81 52-741-2111ynishida@med.nagoya-u.ac.jp
- Yoshihiro Nishida, M.D., Ph.D. · Principal investigator
RecruitingRoyal National Orthopedic Hospital
London, United Kingdom
- Joanne McDonald · Contact
- Joanne McDonald · Principal investigator
RecruitingGlobal Gene Corporation
Mumbai, India
Completed
Study team
Sponsor
Washington University School of Medicine
Study ID 201702006
Principal investigator
Angela Hirbe, M.D., Ph.D.
Washington University School of Medicine
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.